0.2384
0.34%
0.0003
Scisparc Ltd stock is traded at $0.2384, with a volume of 37,112.
It is up +0.34% in the last 24 hours and down -17.62% over the past month.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.2381
Open:
$0.2381
24h Volume:
37,112
Relative Volume:
0.03
Market Cap:
$2.47M
Revenue:
$2.88M
Net Income/Loss:
$-5.12M
P/E Ratio:
-0.000883
EPS:
-269.9888
Net Cash Flow:
-
1W Performance:
+3.46%
1M Performance:
-17.62%
6M Performance:
-79.75%
1Y Performance:
-96.25%
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
SPRC | 0.2389 | 2.47M | 2.88M | -5.12M | 0 | -269.99 |
VRTX | 446.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 740.77 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.86 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. Reports Changes in Financial Position - TipRanks
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks
SciSparc Ltd. Reschedules Annual General Meeting - TipRanks
Examining SPRC’s book value per share for the latest quarter - US Post News
Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex
SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel
SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa
Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga
SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks
FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com
SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire
Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan
SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News
SciSparc signs LOI to sell entire ownership in MitoCareX - MSN
SciSparc Ltd. Proposes Reverse Stock Split - TipRanks
SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada
SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com
SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire
Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News
Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World
Smartgroup Announces Major Shareholding Changes - TipRanks
Science Group PLC Executes Share Buyback - TipRanks
Site Group Plans Massive New Share Issue - TipRanks
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat
CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks
Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
Clearmind, SciSparc slide amid weight-loss study results - MSN
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
UBS Cuts Stake in Spirent Communications - TipRanks
SThree maintains expectations amid tough market conditions. - Research the market
UK recruiter SThree falls on lower Q3 net fee - XM
SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK
Science Group PLC Announces Share Buyback - TipRanks
SThree plc Navigates Market Headwinds in Q3 - TipRanks
SThree Net Fees Fall Amid Challenging Environment - MarketWatch
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World
SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):